Cerus Corporation — Q1 2016 Form 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction of platelets and plasma. The platelet and plasma systems were FDA-approved in December 2014 and are marketed internationally and in the United States. The red blood cell system remained in development, with a European Phase III chronic-anemia trial ongoing and a potential CE mark submission planned for the second half of 2016.
The filing covers the unaudited three months ended March 31, 2016, compared with the three months ended March 31, 2015. Cerus operates in one blood-safety segment. Its common stock outstanding as of April 28, 2016 was approximately 101.7 million shares.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Revenue | $7.6 million | $7.7 million | Down 1% |
| Gross profit | $3.4 million | $3.0 million | Up $0.4 million |
| Gross margin | 44.1% | 38.7% | Up approximately 5.4 points |
| Operating loss | $(15.3) million | $(14.4) million | Loss widened $1.0 million |
| Net loss | $(16.9) million | $(9.5) million | Loss widened $7.4 million |
| Net loss per share, basic | $(0.17) | $(0.10) | More loss per share |
| Net cash used in operations | $(13.0) million | $(15.8) million | Improved $2.7 million |
- Revenue was $7.632 million. Management attributed the decrease primarily to approximately 3% lower disposable-kit volume and approximately 2% Euro depreciation, partially offset by a more favorable product mix.
- Cost of revenue declined 10% to $4.263 million, primarily because inventory had been produced at more favorable foreign-exchange rates. Increased obsolescence and manufacturing charges partly offset the benefit.
- Research and development expense increased 24% to $6.917 million, driven by red blood cell development, platelet and plasma PMA-supplement work, and IDE studies. Selling, general and administrative expense was essentially flat at $11.747 million.
- The prior-year period included a $6.296 million non-cash gain from warrant revaluation. All outstanding warrants were exercised in November 2015, so no comparable gain was recorded in Q1 2016.
- Cash and cash equivalents were $20.8 million at March 31, 2016, down from $71.0 million at December 31, 2015. Short-term investments were $70.5 million and the Aduro marketable-equity investment was $5.1 million, for approximately $96.4 million of cash and investments.
- Total assets were $127.9 million and total stockholders’ equity was $83.5 million. Working capital was approximately $96.6 million, compared with $108.5 million at year-end 2015.
- Total debt was approximately $19.8 million, consisting of $4.5 million current and $15.3 million non-current debt. The term loans mature June 1, 2019; interest-only payments were scheduled through June 2016, subject to an extension if a specified revenue threshold was achieved.
- Cash used in investing activities was $45.0 million, primarily reflecting purchases of investments. Financing activities provided $7.9 million, including $7.1 million of net proceeds from the sale of approximately 1.2 million shares under the Cantor at-the-market facility.
Material changes versus the prior comparable period
- Revenue was broadly stable, but disposable-kit volume declined and foreign-exchange translation remained a headwind.
- Gross margin improved substantially to 44.1% from 38.7%, mainly because of foreign-exchange effects on inventory costs and product mix.
- R&D spending increased by $1.3 million, while SG&A remained flat. Consequently, the operating loss widened to $15.3 million.
- Net loss increased materially because Q1 2015 benefited from the $6.3 million warrant-revaluation gain. Q1 2016 also included $0.8 million of income-tax expense associated largely with changes in the Aduro investment.
- Other comprehensive loss was $20.8 million, including a $3.9 million after-tax unrealized loss on available-for-sale investments, primarily Aduro shares.
- Manufacturing and development obligations related to Fresenius totaled approximately $7.0 million on the balance sheet at March 31, 2016. The 2015 manufacturing and supply agreement eliminated product royalties to Fresenius after June 30, 2015 but imposed additional payment obligations.
- On May 5, 2016, Cerus amended its Cantor agreement, increasing available equity capacity to approximately $70 million, subject to the effectiveness of its shelf registration statement.
Guidance, outlook, commentary, risks and unusual items
- Management expected INTERCEPT disposable-kit revenue to increase over time as U.S. and other market adoption develops, but provided no quantified revenue or earnings guidance.
- Management stated that available cash, cash equivalents, short-term investments and expected product-sale proceeds should fund requirements for at least the next twelve months, while noting that this assessment depends on assumptions that may prove incorrect.
- Cerus expected continued operating losses and additional spending for U.S. commercialization, post-approval studies, regulatory activities, and red blood cell development. Profitability may never be achieved.
- The company planned additional development and chemistry, manufacturing and controls work for a potential red blood cell CE mark submission in the second half of 2016. It did not expect regulatory approval of the red blood cell system within the next twelve months, if ever.
- Access to the remaining $10 million tranche under the Oxford term-loan facility depended on achieving a specified trailing-six-month revenue threshold. The filing states that Cerus might not meet the requirement.
- Contractual obligations totaled approximately $45.0 million, including $24.0 million of debt, $8.5 million of manufacturing and development obligations, $7.9 million of minimum purchase commitments, $3.3 million of operating leases and $1.3 million of other commitments.
- Principal risks include U.S. market adoption and reimbursement, regulatory approvals and post-approval studies, clinical-trial execution, reliance on Fresenius and other sole-source suppliers, inventory obsolescence, foreign-exchange exposure, competition, intellectual-property claims, product liability, and the need for additional capital.
- Two customers represented approximately 48% of trade receivables at March 31, 2016. Significant customers accounted for portions of revenue, including Advanced Technology Comp. KSC at 18%, Medical Device ApS at 11% and Rode Kruis Vlaanderen at 12%.
- Management reported effective disclosure controls as of March 31, 2016, no material changes in internal control over financial reporting, and no legal proceedings.
Important facts for investors to verify
- Whether U.S. adoption of the platelet and plasma systems accelerates sufficiently to offset ongoing R&D and commercialization cash burn.
- The company’s actual cash runway, including the timing of Fresenius obligations, debt amortization and potential red blood cell development costs.
- Whether Cerus achieves the revenue threshold required to access the remaining $10 million term-loan tranche.
- The timing, cost and results of required platelet post-approval studies and the ongoing red blood cell clinical program.
- The effect of Aduro share-price volatility on comprehensive income, liquidity and reported tax expense.
- The extent of future equity issuance under the expanded Cantor facility and the resulting shareholder dilution.
- Supply continuity and pricing under the Fresenius agreement and other sole-source manufacturing arrangements.
- Potential reimbursement, regulatory, intellectual-property and competitive developments affecting U.S. and international commercialization.